1. Home
  2. GMEX vs ONCO Comparison

GMEX vs ONCO Comparison

Compare GMEX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GMEX

GMEX ROBOTICS CORPORATION Class A Ordinary Shares

N/A

Current Price

$0.26

Market Cap

620.0K

ML Signal

N/A

Logo Onconetix Inc.

ONCO

Onconetix Inc.

HOLD

Current Price

$0.72

Market Cap

755.3K

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMEX
ONCO
Founded
2005
2018
Country
Australia
United States
Employees
16
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
620.0K
755.3K
IPO Year
2023
2021

Fundamental Metrics

Financial Performance
Metric
GMEX
ONCO
Price
$0.26
$0.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.6M
13.3M
Earning Date
04-17-2026
06-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.80
EPS
N/A
N/A
Revenue
N/A
$815,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.07
52 Week High
$1.25
$7.65

Technical Indicators

Market Signals
Indicator
GMEX
ONCO
Relative Strength Index (RSI) 29.79 44.32
Support Level N/A $0.62
Resistance Level $0.74 $0.95
Average True Range (ATR) 0.09 0.14
MACD -0.00 -0.03
Stochastic Oscillator 4.80 18.86

Price Performance

Historical Comparison
GMEX
ONCO

About GMEX GMEX ROBOTICS CORPORATION Class A Ordinary Shares

GMEX Robotics Corp is engaged in the design and deployment of AI-powered robotics and intelligent consumer technologies. The group operates in three business areas: Consumer and Commercial Robotics: Developing intuitive and interactive robots designed to assist with daily tasks, provide smart home integration, and offer new levels of convenience and connectivity to boost productivity; AI-Driven Hardware: Embedding artificial intelligence into physical products to create self-learning and adaptive user experiences; and Innovation & Ecosystem: Building a robust ecosystem of robotic products that communicate and evolve, powered by proprietary AI algorithms.

About ONCO Onconetix Inc.

Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Share on Social Networks: